First-and-only FcRn blocker to demonstrate superiority in activities of daily living (MG-ADLa) over placebo when added to standard of care over 24 weeks in antibody positive patients: anti-AChR+, anti-MuSK+, anti-LRP4+ HELSINKI, June 28, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive results from the nipocalimab Phase 3 Vivacity-MG3 study in patients with generalized myasthenia gravis (gMG). Patients treated with nipocalimab plus standard of care (SOC) achieved superiority over ...

Johnson & Johnson's business is growing at a decent rate, but there's still a fair bit of risk surrounding the company. Johnson & Johnson (JNJ -0.25%) is focusing on the next iteration of its business -- one that investors hope creates a lot more growth than in years past. The company spun off its consumer health business last year, and with just two main segments moving forward -- medical devices and innovative medicines -- J&J could be in a good position to accelerate its growth rate. But investors don't ...

The latest trading session saw Johnson & Johnson (JNJ) ending at $147.19, denoting a -1.29% adjustment from its last day's close. This move lagged the S&P 500's daily gain of 0.09%. Meanwhile, the Dow experienced a drop of 0.1%, and the technology-dominated Nasdaq saw an increase of 0.16%. Prior to today's trading, shares of the world's biggest maker of health care products had gained 1.46% over the past month. This has lagged the Medical sector's gain of 2.3% and the S&P 500's gain of 2.83% in that time. T ...

J&J is the textbook blue chip stock -- but it's not for everyone. Investing comes in many flavors, so there isn't a right or wrong approach: You should do what's best for you. That applies even to dividend investing. For some, dividend investing means maximizing immediate income, even if it requires sacrificing some growth and long-term upside; for others, it's the opposite. Healthcare juggernaut Johnson & Johnson (JNJ 0.25%) is a hallowed name in the dividend community, both for its brand recognition and f ...

blackred FOMO (fear of missing out) is hard to ignore when it comes to buying stocks in today's market, especially when influencers post headline-making comments about meme stocks like GameStop (GME) or when expensive stocks just keep going up, as in the case of Nvidia (NVDA), whose market cap just surpassed that of Microsoft (MSFT) to become the world's most valuable company. I'm not bothered, however, by not participating in the aforementioned stock rallies as I'm happy to layer into discounted dividend s ...

Johnson & Johnson (JNJ) announced that it has submitted a supplemental biologics license application (sBLA) seeking approval of its immunology drug, Tremfya, for a new indication — moderately to severely active Crohn’s disease (CD). This marks the second label expansion filing for Tremfya in three months, following the sBLA in active ulcerative colitis (UC) indication that was filed in March. Tremfya is currently approved to treat certain patients with plaque psoriasis and active psoriatic arthritis in seve ...

Submission is supported by 48-week results from the Phase 3 GALAXI and GRAVITI programs TREMFYA® is the only IL-23 inhibitor to demonstrate strong endoscopic outcomes with subcutaneous (SC) induction, consistent with intravenous (IV) induction, and has the potential to be the first in its class to offer the option of both SC and IV induction therapy in Crohn's disease GALAXI includes data demonstrating superior outcomes for TREMFYA® versus STELARA® (ustekinumab) in Crohn's disease SPRING HOUSE, Pa., June 20 ...

文章核心观点 - 强生公司宣布其生物制剂TREMFYA®在III期克罗恩病临床试验中达到了所有主要和次要终点指标 [1][2][3] - TREMFYA®在克罗恩病治疗中展现出良好的疗效和安全性,有望成为唯一一种能够提供皮下和静脉注射两种给药途径的IL-23抑制剂 [2][3] - 该结果将在即将召开的医学会议上公布,并将提交给监管机构 [4] 根据目录分别总结 TREMFYA®在克罗恩病中的临床试验 - GRAVITI是一项随机、双盲、安慰剂对照的III期临床试验,评估TREMFYA®皮下给药方案在中重度活动性克罗恩病患者中的疗效 [6] - GALAXI是一项II/III期临床试验项目,评估TREMFYA®在中重度活动性克罗恩病患者中的疗效和安全性,包括与STELARA®的对照研究 [7] 克罗恩病的概况 - 克罗恩病是一种慢性肠道炎症性疾病,目前尚无治愈方法 [8][9] - 该病影响了约300万美国人和400万欧洲人,症状包括腹痛、腹泻、体重下降等 [8][9] TREMFYA®的机制和适应症 - TREMFYA®是强生公司开发的首个完全人源化的双效单克隆抗体,通过抑制IL-23发挥治疗作用 [10] - TREMFYA®已获批用于治疗中重度斑块状银屑病和活动性银屑病性关节炎 [11]

Patients who received nipocalimab 15 mg/kg demonstrated a greater than 70 percent relative average improvement on the primary endpoint compared to patients who received placebo Sjögren's disease is a chronic, debilitating, and prevalent autoantibody disease with no approved advanced treatments VIENNA, June 15, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announces patients treated with nipocalimab demonstrated statistically significant (P=0.002) and clinically meaningful improvement in ClinESSDAIa sco ...

24-month overall survival rate of 67 percent achieved with TALVEY® 0.8 mg/kg biweekly dosing in the Phase 1/2 MonumenTAL-1 study MADRID, June 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that long-term data from the Phase 1/2 MonumenTAL-1 study showed that with 20 to 30 months of median follow-up, triple-class- exposed patients with relapsed or refractory multiple myeloma (RRMM) who were treated with TALVEY® (talquetamab-tgvs) maintained high overall response rates (ORR) and durabl ...